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Context
Although the EU Council stated[1] that “All health systems
in the EU aim to make provision, which is patient-centered
and responsive to individual need”, numerous sources
show important and unacceptable differences in access to
orphan drugs in the Member States of the European
Union (EU COM [2], EURORDIS [3,4], BE EU Presidency
[5,8], EU Council [6]). With this regard, in the context of
the 2010 Belgian EU presidency initiative on ‘Innovation
and Solidarity’ and within the framework of the process
on corporate responsibility in the field of pharmaceuticals
[7], EU Commissioner Tajani launched the project
Mechanism of Coordinated Access to Orphan Drugs.
Objectives
Design a concrete operational mechanism of coordinated
access to orphan drugs for patients, stakeholders and
Member States. Through coordination and cooperation
between stakeholders and Member States at EU level, real
access is to be provided to orphan medicinal products for
patients with unmet medical needs and for whom these
solutions would otherwise be out of reach – in an afford-
able and sustainable way (“real life access”).
Methodology
The project is managed by Belgium(NIHDI), supported
by the European Commission (ENTR, SANCO, COMP,
MARKET) and Eminet. Thirteen other Member States
(Austria, Estonia, Finland, France, Greece, Hungary, Italy,
Malta, Netherlands, Poland, Portugal , Spain, Sweden)
are participating, together with the different stakeholders
(AIM, EPF, ESIP, EURORDIS, CPME, EFPIA, EGA,
EuropaBio, GIRP). Three Work packages (WP) cover the
three different aspects of granting effective access to
medicines (WP1: Identifying and assessing a relevant
orphan drug , WP2: Selection of the target population
and mechanisms of funding , WP3: Treatment ). In each
WP operational steps and implementing activities were
identified. Feasibility at present and opportunities for
near future development of desirable coordinated activ-
ities were studied, and no-go solutions were documented
and rejected. Integrating the three WP will lead to the
development of implementable scenarios for pilot pro-
jects and result in policy recommendations.
Discussion
Guaranteeing an added value for all stakeholders and espe-
cially from a patient’s perspective through cooperation and
coordination is the main objective of the project. Although
coordinated access at an European level will be organised
on a voluntary basis, at some point in time, some sort of
commitment from the participating partners is required.
Moreover, it is crucial that the subsidiarity principle is not
compromised in any way. Duplication of efforts will be
avoided and previously made investments – in terms of
financial and human resources, expertise and experience -
(ex. by EUnet HTA, EMA COMP, EUCERD, CAVOD) will
be valorised.
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